Domicilium Real Estate Fund III LP 4

What Happened Domicilium Real Estate Fund III LP, a reported 10% holder of Eloxx Pharmaceuticals (ELOX), exchanged common stock for pre‑funded warrants on May 27, 2026. The Form 4 shows 113,636 common shares disposed at $0.00 (reflecting an exchange) and 113,636 pre‑funded warrants acquired (derivative). No cash changed hands in the transaction — it was a stock‑for‑warrant conversion rather than an open‑market sale.

Key Details

• Transaction date: 2026-05-27 (Form 4 filed 2026-06-05 — late filing).
• Reported entries: 113,636 shares disposed at $0.00; 113,636 pre‑funded warrants acquired (derivative, price N/A).
• Footnote context: The exchange involved 1,250,000 pre‑split shares for pre‑funded warrants; an 11-for-1 reverse stock split effective May 29, 2026, is reflected (1,250,000 ÷ 11 ≈ 113,636).
• Pre‑funded warrants: no expiration, exercisable any time, but exercise is capped so holder (with affiliates) cannot exceed 4.99% ownership upon exercise.
• Beneficial ownership: Securities are directly owned by the Fund and may be indirectly beneficially owned by Domicilium entities and Daniel Simon (managing member). Reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
• Shares owned after transaction: not specified in the provided filing summary.

Context This was a conversion of common shares into pre‑funded warrants by an institutional 10% holder, not an executive or routine open‑market purchase/sale. Such exchanges are financing/structure decisions and do not directly signal a traditional buy or sell decision by company insiders. The late filing may matter for disclosure timing but does not change the nature of the transaction.